About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Biosimilars Hold Promise for Treating Rheumatic Diseases

by Colleen Fleiss on February 9, 2018 at 12:17 AM
Font : A-A+

Biosimilars Hold Promise for Treating Rheumatic Diseases

A new whitepaper published in the Arthritis & Rheumatology, the American College of Rheumatology (ACR) journal reveals about the potential use of biosimilars in clinical practice for the treatment of a variety of medical conditions such as rheumatic diseases, and possibly at a reduced cost.

While the initial position of the ACR on biosimilars urged caution as the products were being developed, evaluated, and approved, this latest Whitepaper notes that healthcare providers should now incorporate biosimilars, where appropriate, into their regimens to treat patients with rheumatic diseases. "Now that biosimilars have been used successfully in Europe, with rigorously acquired data supporting their broader use, and as the US is on the verge of a similar transition, the ACR is poised to reconsider its position," the authors wrote.

Advertisement


The paper also stresses that communication between providers, pharmacists, and patients will be critical to alleviate anxiety and reduce skepticism regarding the use of newly available agents. "We remain optimistic that the use of biosimilars will improve patient access to biologic agents, allowing continued delivery of high quality healthcare to be realized at a lower cost to the individual patient," the authors wrote.

An accompanying editorial by Dr. Roy Fleischmann, of the University of Texas Southwestern Medical Center and Metroplex Clinical Research Center in Dallas notes that there are many clear statements (white), but there are also arguments that are open to alternative opinions (gray) and arguments that are open to an alternative conclusion (black). "It is not at all clear that a biosimilar will be cheaper to the patient - it may be cheaper to the pharmacy benefit management firm, but this may not really help patient access to these medications. It is also not clear that non-medical substitution will be effective in every patient nor has it been demonstrated that extrapolation is effective, said Dr. Fleischmann. "These are the major questions remaining unanswered with respect to the use of biosimilars in rheumatic disease."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.


Recommended Reading
Rheumatic Fever
Rheumatic fever is an inflammatory disease that may develop after an infection with group A ......
Quiz on Arthritis
Do you know that there are more than 100 types of arthritis? If you think that only old people ......
Regulatory Agencies Monitor Approval to New Therapies While Ensuring Safety of Medicines
Regulators work by balancing both the accelerated approval of new medicines while monitoring the ......
More Doctors Use Ultrasound to Diagnose and Manage Rheumatic Diseases
Recent trends highlight the fact that more rheumatologists are using musculoskeletal ultrasound ......

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use